top | item 6732636

(no title)

sgarlatm | 12 years ago

It's nice to know that despite all the alarmist articles about the end of antibiotics, good progress is being made. If this works, it could completely replace traditional antibiotics. In that case, I could see dozens of new drugs in this class developed by the antibiotic companies. This would be similar to the race to develop new antidepressants, HIV drugs, and erectile dysfunction drugs. Any drug you have to take over and over again is a huge draw for the pharmaceuticals.

discuss

order

giarc|12 years ago

This won't completely replace traditional antibiotics. As the article states this acts on Gram positive persister cells (a very specific group). The coming storm is from Gram negative bacteria such as Klebsiella, Actinetobacter and Pseudomonas.

There is actually very little activity occurring in the field of antibiotic drug discovery and you identified the issue; no money in drugs that someone takes for 14 days and stops. Pharmaceutical companies are driven by stockholders and therefore they want them developing drugs that someone takes for the rest of their life (anti-depressants). Much of the research for abx discovery comes from academia who struggle with budgets that are pennies compared to what Pfizer, GSK, Wyeth, Astra can afford.

JunkDNA|12 years ago

You're right that it's about profits when pharma is involved, but you are wrong about the reason (otherwise vaccines would not exist). I can tell you from firsthand experience that the length of time someone is on a drug makes almost no difference in where research priorities are.

The primary issue with antibiotics is that since the late 1990's, if you succeed, and you develop the best antibiotic the world has ever seen, the FDA will require it to be a "drug of last resort". It will therefore sit on the shelf and be guaranteed to not be prescribed very much during the life of its patent. Once enough time goes by, and other drugs come out if (and that's a big if) it is no longer a drug of last resort, it is likely off patent and therefore can be made in generic form for pennies by generic manufacturers. Regardless of what you think about patents, these incentives are completely misaligned with companies going all-in and taking a risk on new antibiotics.

larrys|12 years ago

"no money in drugs that someone takes for 14 days and stops. Pharmaceutical companies are driven by stockholders"

You wonder of course why, if that is the case (and I do agree), that the government doesn't get involved with more funding or subsidies for these types of less profitable drugs. The same way they spend countless dollars on other things for the public good (and company profit obviously).

w1ntermute|12 years ago

Sounds like something the Gates Foundation should get on.

im3w1l|12 years ago

The scary thing is what would happen if these bacteria fell into the hands of terrorist extremists. They could potentially create bio-weapons of mass destruction. Or imagine if some suicide cult decided that the time has come for the doomsday of reckoning. Al-Qaeda anthrax letters are nothing compared to this. It could also be used to threaten mutually assured destruction in asymmetric warfare. Iran could probably develop it more easily and stealthily than their (not very) secret nuke program. Developing countermeasure to this is a matter of national security. Insha'Allah people will come to their senses and please think of the children: We must secure the existence of our people and a future for white children before it is too late.

-----BEGIN PGP MESSAGE-----

.

jA0EAwMCRocgNS5lXxmuyT+0aXL2u7pKyJ0+BNTpPRy33dvnVrD4SVfqcF+oTDUx vLOi4p3oM6sJn80NnTUCGjqlpEPuekIIRXWAjOtq+P4= =+4PK

-----END PGP MESSAGE-----

zabraxias|12 years ago

This is really fantastic news but I too am skeptical of the drug companies being interested in a cure as opposed to a repeatable treatment.

As a side note the article seems very well written for non-medical folks like myself.

Fomite|12 years ago

This line of reasoning doesn't really apply to antibiotics - because you're likely to get another infection in your lifetime, and many people have infections at any given time, they're perfectly fine eradicating this one.

Believe me, in the infectious disease space, drug companies tend to look for cures and prevention. For example, Merck and GSK spent staggering amounts of money on the HPV vaccine.